STK11 and prostate cancer: Interestingly, the expression of either wild-type LKB1, or a kinase-dead form of LKB1 (LKB1K78I) is sufficient to reduce tumor burden and impair metastatic potential of DU145 prostate cancer cells that lack LKB1, indicating LKB1 may also elicit a kinase-independent tumor suppressive function [215].